An official website of the United States government
Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability — Sickle Cell Data Collection Program, 11 States, 2016–2020
Weekly / March 28, 2024 / 73(12);248–254
Please note: This report has been corrected.
Mariam Kayle, PhD1; Audrey L. Blewer, PhD1,2; Wei Pan, PhD1,2; Jennifer A. Rothman, MD2; Carri S. Polick, PhD1,3; Joshua Rivenbark, MD, PhD4; Elliott Fisher, MS5; Camila Reyes, MS5; John J. Strouse, MD, PhD2; Shelby Weeks, MHS6; Jay R. Desai, PhD7; Angela B. Snyder, PhD8; Mei Zhou, MS8; Ankit Sutaria, MBBS9; Jhaqueline Valle, MPH10; Sophia S. Horiuchi10; Marci K. Sontag, PhD11; Joshua I. Miller, MPH11; Ashima Singh, PhD12; Mahua Dasgupta, MS12; Isaac A. Janson, PhD13; Najibah Galadanci, PhD14; Sarah L. Reeves, PhD15; Krista Latta, MPH15; Isabel Hurden, MPH16; Shamaree J. Cromartie, MPH17; Allison P. Plaxco, MPH18; Ayesha Mukhopadhyay, MPH18; Matthew P. Smeltzer, PhD18; Mary Hulihan, DrPH19 (View author affiliations)
View suggested citationSummary
What is already known about the topic?
Approximately one in every 365 Black or African American (Black) newborns in the United States has sickle cell disease (SCD), a condition associated with complex health needs.
What is added by this report?
During 2016–2020, 3,305 cases of SCD among newborns were recorded across 11 states participating in the Sickle Cell Data Collection program (SCD birth prevalence = 28.54 per 10,000 [one in every 350] non-Hispanic Black newborns). Approximately two thirds of mothers of newborns with SCD resided in counties with high or very high social vulnerability.
What are the implications for public health?
Implementation of tailored interventions, including increasing access to transportation, improving housing, and advancing equity in high vulnerability areas, could facilitate care and improve health outcomes for children with SCD.
Altmetric:
Abstract
Sickle cell disease (SCD) remains a public health priority in the United States because of its association with complex health needs, reduced life expectancy, lifelong disabilities, and high cost of care. A cross-sectional analysis was conducted to calculate the crude and race-specific birth prevalence for SCD using state newborn screening program records during 2016–2020 from 11 Sickle Cell Data Collection program states. The percentage distribution of birth mother residence within Social Vulnerability Index quartiles was derived. Among 3,305 newborns with confirmed SCD (including 57% with homozygous hemoglobin S or sickle β-null thalassemia across 11 states, 90% of whom were Black or African American [Black], and 4% of whom were Hispanic or Latino), the crude SCD birth prevalence was 4.83 per 10,000 (one in every 2,070) live births and 28.54 per 10,000 (one in every 350) non-Hispanic Black newborns. Approximately two thirds (67%) of mothers of newborns with SCD lived in counties with high or very high levels of social vulnerability; most mothers lived in counties with high or very high levels of vulnerability for racial and ethnic minority status (89%) and housing type and transportation (64%) themes. These findings can guide public health, health care systems, and community program planning and implementation that address social determinants of health for infants with SCD. Implementation of tailored interventions, including increasing access to transportation, improving housing, and advancing equity in high vulnerability areas, could facilitate care and improve health outcomes for children with SCD.
Introduction
Sickle cell disease (SCD) is an inherited blood disorder caused by mutations in the hemoglobin subunit beta (HBB) gene and is associated with premature mortality (1) and significant morbidity, including vasoocclusive pain, stroke, and multiorgan damage. The protective association between variants in HBB and severe Plasmodium falciparum malaria results in a higher prevalence of HBB mutations in geographic areas with high malaria prevalences (2). The combination of this protective effect and the historical trans-Atlantic slave trade has resulted in SCD primarily affecting Black or African American (Black) persons in the United States, leading to exacerbation of high disease-associated morbidity in groups affected by structural racism and health inequities. Social determinants of health further contribute to poor outcomes among persons with SCD (3,4). Because of the associated health inequities, high risk of lifelong disabilities, and high cost of care, managing SCD remains a major national public health priority (5).
Although universal newborn screening for hemoglobinopathies, including SCD, has been implemented nationally since 2006 (6), SCD birth prevalence data remain scarce. The most recent race-specific birth prevalence (one in 365 Black newborns) is based on 2007 data (7). Data from 2015–2017 indicate an overall SCD birth prevalence of one in 2,024 U.S. newborns (8). The CDC-funded Sickle Cell Data Collection (SCDC) program is well suited to estimate SCD birth prevalence. At the time of this analysis, SCDC included 11 state-level surveillance programs from the southern, midwestern, and western United States. The programs collect and analyze data on newborns with SCD, including SCD type and geographic location, allowing for the assessment of county-level socioeconomic conditions that influence health outcomes among infants with SCD. Identifying these conditions can guide the planning and implementation of public health, health care systems, and community programs supporting persons with SCD. This report analyzed state newborn screening program records from 2016–2020 from 11 SCDC program states to provide updated crude and race-specific SCD prevalence among newborns and to describe the percentage of newborns with SCD by county-level socioeconomic characteristics among these states.
Methods
Data Sources
State newborn screening records from 2016–2020, combined with birth certificate data and confirmation testing results when available, were used to identify the most recent data across 11 SCDC program states (Alabama, California, Colorado, Georgia, Indiana, Michigan, Minnesota, North Carolina, Tennessee, Virginia, and Wisconsin). Newborns with a confirmed diagnosis of SCD were included if the infant’s birth and their mother’s residence county were within the SCDC program state. Confirmed SCD diagnosis was based on a positive Clinical Laboratory Improvement Amendments (CLIA)–certified laboratory SCD test result reported by a state newborn screening program with confirmatory testing or clinical diagnosis by a physician and documented confirmatory CLIA-certified laboratory testing after the newborn period. The mother’s residence county and infant’s race, ethnicity, sex, date of birth, and SCD type were extracted from newborn screening records or birth certificate data. Infants’ race, ethnicity, and SCD type were based upon state-specific methodologies across newborn screening programs (9). The total number of live births and of live births among non-Hispanic Black persons by county were obtained from each state’s health department.
Data Analysis
Crude SCD birth prevalence (calculated by dividing the number of newborns with SCD by the total number of live births) and SCD birth prevalence among non-Hispanic Black newborns (calculated by dividing the number of Black* newborns with SCD by the total number of live births among non-Hispanic Black† persons) were reported per 10,000 newborns. Prevalence rates were calculated overall and by state.
County Social Vulnerability Index (SVI) characteristics were quantified using the 2020 state-specific SVI databases based on the birth mother’s county of residence at birth. The state-specific SVI ranks each county relative to other counties within the state on 16 social factors. Percentile ranking values range from 0 to 1, with higher values indicating greater vulnerability. An overall SVI percentile ranking as well as percentile rankings measured on four themes (socioeconomic status, household characteristics, racial and ethnic minority status, and housing type and transportation)§ were categorized into quartiles from least to most vulnerable: low (0 to 0.25), medium (>0.25 to 0.5), high (>0.5 to 0.75), and very high (>0.75 to 1.0) vulnerability. The percentage distribution of birth mother residence within SVI quartiles was derived for the overall SVI measure and by SVI themes.
SAS (version 9.4; SAS Institute) was used for all analyses. Institutional review boards or ethics committees overseeing each state program either determined the analysis to be outside purview as public health surveillance or exempt and approved a waiver of consent. This activity was reviewed by CDC, deemed not research, and was conducted consistent with applicable federal law and CDC policy.¶
Results
Demographics and Birth Prevalence
During 2016–2020, a total of 3,305 SCD-affected newborns were recorded across the 11 SCDC program states (Table 1). The highest number of SCD-affected newborns (758) occurred in Georgia, followed by North Carolina (435), California (419), and Alabama (386). Approximately 50% of newborns with SCD were male, 90% were Black, and 4% were Hispanic or Latino. Overall, 1,882 (57%) infants had homozygous hemoglobin S (HbSS) or sickle β-null thalassemia (HbSβ0), 28% had hemoglobin SC disease, and 10% had sickle β-plus thalassemia (HbSβ+) or another SCD type.** Across the 11 states, crude SCD birth prevalence was 4.83 per 10,000 (one in every 2,070) live births (Table 2). SCD birth prevalence among non-Hispanic Black newborns was 28.54 per 10,000 (one in every 350) live births.
Social Vulnerability
Among all mothers of newborns with SCD, approximately two thirds (67%) lived in counties with high or very high social vulnerability (Figure). In five of the 11 SCDC program states, more than one half of birth mothers resided in very high SVI counties (Wisconsin [86%], Indiana [82%], Michigan [61%], Tennessee [58%], and California [56%]) (Supplementary Figure, https://stacks.cdc.gov/view/cdc/151052). Approximately one half (49%) of mothers of newborns with SCD resided in areas with high or very high socioeconomic vulnerability and household characteristic vulnerability (56%). In addition, approximately two thirds (64%) of mothers resided in counties with high or very high housing type and transportation vulnerability, and 89% resided in counties with high or very high racial and ethnic minority status vulnerability (Figure).
Discussion
In this analysis of birth prevalence and social vulnerability ranking of newborns with SCD across 11 SCDC program states, SCD affected one in every 2,070 newborns overall and one in every 350 non-Hispanic Black newborns. These findings align with previously reported estimates of SCD affecting one in every 2,024 newborns overall and one in every 365 non-Hispanic Black newborns (7,8); however, they expand on those reports by using more recent data from 2016–2020.
The finding that most mothers lived in counties with high or very high SVI highlights the insights that county-level data can provide to public health policymakers when considering the support that community-based programs can deliver to meet the complex health needs of newborns with SCD and their caregivers. The majority (64%) of mothers of newborns with SCD resided in counties with high or very high housing type and transportation social vulnerability, underscoring potential strategies to serve these communities, including medical transportation programs or development of innovative care models to facilitate access to comprehensive SCD care. For example, improving flexibility in scheduling of medical transportation, providing reimbursement for use of existing public transportation such as rideshares, and partnering with local faith- and community-based organizations for medical transport have the potential to improve access to care. Moreover, understanding the geographic location of SCD-affected newborns within a state can help guide specialty and primary care efforts to improve access to SCD care. Together, these findings provide data to Medicaid programs, the primary payer for SCD care,†† as they collaborate with state agencies to consider the effect of housing and transportation vulnerabilities on infants with SCD. These Medicaid programs can also support partnerships created by public health programs, the communities they serve, and community-based organizations to ascertain specific resource needs of SCD-affected populations, as well as where and how resources can be deployed to drive more equitable outcomes.
Limitations
The findings in this report are subject to at least four limitations. First, because of the time needed to ascertain SCD type by public health surveillance systems, state newborn screening data are subject to a 3-year time lag. Despite this lag, SCD counts among newborns did not fluctuate significantly between years. Second, missing data hampered the ability to further disaggregate race and ethnicity categories, which might be important to understanding differential birth prevalences across states and tailoring programs to different racial and ethnic communities. Third, SVI was examined at the county level as opposed to U.S. Census Bureau tract level, which could mask variations of SVI within counties. Finally, SVI metrics are at the county level rather than the person level and might not reflect a comprehensive assessment of specific services needed by infants with SCD.
Implications for Public Health Practice
Understanding characteristics of the geographic residence of infants with SCD and their caregivers is critical to guiding local and state health departments and health agencies in prioritizing and developing programs that can mitigate specific social determinants of health and their attendant inequities. Specifically, these data highlight the potential need to consider tailored interventions in high vulnerability areas to increase access to transportation, improve housing, and advance equity for infants with SCD. Developing programs in partnership with communities and community-based organizations is critical to allocating needed resources and determining how they might be effective in improving health outcomes for children with SCD.
Corresponding author: Mary Hulihan, mhulihan@cdc.gov.
1Duke University School of Nursing, Durham, North Carolina; 2Duke University School of Medicine, Durham, North Carolina; 3Durham VA Health Care System, Durham, North Carolina; 4Division of Hematology, University of North Carolina, Chapel Hill, North Carolina; 5Duke Office of Clinical Research, Duke University School of Medicine, Durham, North Carolina; 6Division of Public Health, North Carolina Department of Health and Human Services; 7Minnesota Department of Health; 8Georgia Health Policy Center, Georgia State University, Atlanta, Georgia; 9Georgia Department of Public Health; 10Tracking California, Public Health Institute, Richmond, California; 11Center for Public Health Innovation at CI International, Littleton, Colorado; 12Medical College of Wisconsin, Milwaukee, Wisconsin; 13Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana; 14University of Alabama at Birmingham, Birmingham, Alabama; 15Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan; 16Michigan Department of Health and Human Services; 17Virginia Department of Health; 18Division of Epidemiology, Biostatistics and Environmental Health, School of Public Health, The University of Memphis, Memphis, Tennessee; 19Division of Blood Disorders and Public Health Genomics, National Center on Birth Defects and Developmental Disabilities, CDC.
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Sophia S. Horiuchi reports ownership of Natera stock and stock options and of Roche stock by her spouse. Mariam Kayle reports institutional support from Agios Medical Education Program and Novo Nordisk Independent Medical Education Activity to support the 11th Annual Sickle Cell Conference, September 8–9, 2023; receipt of consulting fees from Loyola University; receipt of honorarium for being an ad hoc reviewer from the National Institutes of Health (NIH), Center for Scientific Review, Social and Environmental Determinants of Health Study Section; and uncompensated membership in the American Society of Hematology Research Collaborative Data Hub Oversight Group, Sickle Cell Disease Subcommittee. Carri S. Polick reports support from the Veterans Administration and Duke University Clinical and Translational Science Institute. Ashima Singh reports institutional support from NIH, National Heart, Lung, and Blood Institute, the National Institute of Neurological Disorders and Stroke, and the Health Resources and Services Administration (HRSA) Sickle Cell Treatment Demonstration Program. John J. Strouse reports institutional support from the HRSA Southeast Region Coordinating Center Sickle Cell Treatment Demonstration Program and the North Carolina State Department of Health Sickle Cell Syndrome Program for the Duke Adult and Pediatric Sickle Cell Program; royalties from UpToDate for preparation of guidance on the use of hydroxyurea for sickle cell disease (SCD); consulting fees for GLG telephone consultation on SCD and Guidepoint telephone consultation on SCD; receipt of honoraria from the University of Rochester-Equity in Sickle Cell Disease Care; payment for medical legal expert testimony from Emory University in a case involving emergency department care of an adult with sickle beta thalassemia; travel support from the American Society of Hematology Sickle Cell Learning Community Meeting and Sickle Cell Disease Association of America Meeting to speak on behalf of the American Society of Hematology and travel support from the American Thrombosis Hemostasis Network Data Summit as an invited speaker on gene therapy for SCD: Design for Equity; payment for participation on a data safety monitoring board for disc medicines for phase 1 trial planning for bitopertin for SCD; and service as vice president of the Sickle Cell Adult Provider Network. No other potential conflicts of interest were disclosed.
* The number of newborns with SCD was reported to the SCDC programs with separate variables for race and ethnicity. As a result, the numerator in the calculation of SCD birth prevalence includes all Black newborns with SCD, regardless of ethnicity.
† The number of live births was reported to the SCDC programs with a single, combined variable for race and ethnicity. As a result, the denominator in the calculation of SCD birth prevalence includes only non-Hispanic Black newborns. Because the count of Black newborns with SCD included all ethnicities but the count of all Black live births included non-Hispanic newborns only, the non-Hispanic Black SCD birth prevalence could be overestimated.
§ https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html
¶ 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.
** start highlightHemoglobin SS disease (HbSS)end highlight is usually the most severe type of SCD; children inherit a hemoblobin S gene from each parent. Persons with HbSC disease inherit a hemoglobin S gene from one parent, and a gene for abnormal hemoglobin C from the other parent; HbSC is usually milder than HbSS. Children with HbSβ inherit the hemoglobin S gene from one parent and a β thalassemia gene from the other parent. HbSβ0 is usually more severe than is HbSβ+. Rarer SCD types include HbSD, HbSE, and HbSO, in which an abnormal D, E, or O hemoglobin gene is inherited from one parent, and the hemoglobin S gene is inherited from the other parent. https://www.cdc.gov/ncbddd/sicklecell/facts.html
References
- Payne AB, Mehal JM, Chapman C, et al. Trends in sickle cell disease-related mortality in the United States, 1979 to 2017. Ann Emerg Med 2020;76(3S):S28–36. https://doi.org/10.1016/j.annemergmed.2020.08.009 PMID:32928459
- Esoh K, Wonkam A. Evolutionary history of sickle-cell mutation: implications for global genetic medicine. Hum Mol Genet 2021;30(R1):R119–28. https://doi.org/10.1093/hmg/ddab004 PMID:33461216
- Phillips S, Chen Y, Masese R, et al. Perspectives of individuals with sickle cell disease on barriers to care. PLoS One 2022;17:e0265342. https://doi.org/10.1371/journal.pone.0265342 PMID:35320302
- Tanabe P, Myers R, Zosel A, et al. Emergency department management of acute pain episodes in sickle cell disease. Acad Emerg Med 2007;14:419–25. https://doi.org/10.1111/j.1553-2712.2007.tb01801.x PMID:17389246
- CDC. Sickle cell disease: about CDC’s work on sickle cell disease. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. Accessed July 17, 2023. https://www.cdc.gov/ncbddd/sicklecell/about.html#:~:text=CDC%20strives%20to%20educate%20people,SCD%20among%20the%20general%20public
- Benson JM, Therrell BL Jr. History and current status of newborn screening for hemoglobinopathies. Semin Perinatol 2010;34:134–44. https://doi.org/10.1053/j.semperi.2009.12.006 PMID:20207263
- Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010;38(Suppl):S512–21. https://doi.org/10.1016/j.amepre.2009.12.022 PMID:20331952
- Sontag MK, Yusuf C, Grosse SD, et al. Infants with congenital disorders identified through newborn screening—United States, 2015–2017. MMWR Morb Mortal Wkly Rep 2020;69:1265–8. https://doi.org/10.15585/mmwr.mm6936a6 PMID:32915168
- APHL. Hemoglobinopathies: current practices for screening, confirmation and follow-up. Silver Spring, MD: Association of Public Health Laboratories; 2015. Accessed August 22, 2023. https://www.aphl.org/aboutAPHL/publications/Documents/NBS_HemoglobinopathyTesting_122015.pdf
Abbreviations: HbSC = hemoglobin SC disease; HBSS = sickle cell homozygous hemoglobin S; HbSβ0 = sickle beta-null thalassemia; HbSβ+ = sickle beta-plus thalassemia; NH = non-Hispanic; SCD = sickle cell disease; Unk = unknown.
* Ethnicity was unknown in 18% of cases; therefore, ethnicity results should be interpreted with caution.
† Dashes indicate data was censored because counts were <11 in one or more cells.
Abbreviations: Black = Black or African American; NH = non-Hispanic; SCD = sickle cell disease; SCDC = Sickle Cell Disease Collection.
* Crude prevalence of newborns with SCD were calculated by dividing the number of newborns with SCD by number of live newborns in each state and multiplying by 10,000.
† The number of newborns with SCD was reported to SCDC programs with separate variables for race and ethnicity. As a result, the numerator in the calculation of SCD birth prevalence includes all Black newborns with SCD, regardless of ethnicity.
§ The number of live births was reported to SCDC programs with a single, combined variable for race and ethnicity. As a result, the denominator in the calculation of SCD birth prevalence includes only NH Black newborns.
¶ Prevalence of NH Black newborns with SCD was calculated by dividing the number of Black newborns with SCD by number of live births among NH Black persons in each state during 2016–2020 and multiplying by 10,000. Birth rates among NH Black persons for Alabama, Colorado, and Indiana should be interpreted with caution because race was unknown for 9%–14% of newborns with SCD in these states; thus, the NH Black SCD birth prevalence for these states could be underestimated.
FIGURE. Percentage of mothers of newborns with sickle cell disease (N = 3,305), by overall and theme-specific Social Vulnerability Index quartiles* — 11 Sickle Cell Data Collection program states,† 2016–2020
Abbreviation: SVI = Social Vulnerability Index.
* The 2020 state-ranked SVI datasets based on mother’s county of residence at birth were used (https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html). SVI values were state-specific and ranked each county relative to other counties within a state. The SVI ranks counties based on 16 social factors. Percentile ranking values range from 0 to 1, with higher values indicating greater vulnerability. Themes were socioeconomic status (<150% of the federal poverty level, unemployed, housing cost burden, no high school diploma, and no health insurance), household characteristics (age ≥65 years, age ≤17 years, civilian with a disability, single-parent households, and English language proficiency), racial and ethnic minority status (non-Hispanic American Indian or Alaska Native, non-Hispanic Asian, non-Hispanic Black or African American, non-Hispanic Native Hawaiian or other Pacific Islander, non-Hispanic two or more races, Hispanic or Latino of any race, and non-Hispanic other races), and housing type and transportation (multiunit structures, mobile homes, crowding, no vehicle, and group quarters). For 127 (4%) mothers of newborns with sickle cell disease, the county of residence at birth was unknown.
† Alabama, California, Colorado, Georgia, Indiana, Michigan, Minnesota, North Carolina, Tennessee, Virginia, and Wisconsin.
Suggested citation for this article: Kayle M, Blewer AL, Pan W, et al. Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability — Sickle Cell Data Collection Program, 11 States, 2016–2020. MMWR Morb Mortal Wkly Rep 2024;73:248–254. DOI: http://dx.doi.org/10.15585/mmwr.mm7312a1.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.